Treatment Options for Symptomatic Uterine Fibroids

Medical Management Options

The American College of Radiology recommends medical management as first-line therapy for symptomatic uterine fibroids before pursuing more invasive treatments 1, 2
NSAIDs and estrogen-progestin oral contraceptives are recommended as first-line treatments for reducing bleeding symptoms associated with uterine fibroids, with a strength of evidence level of moderate to high 2, 3
Tranexamic acid is an effective nonhormonal alternative for patients who cannot use hormonal options, with a significant reduction in bleeding symptoms 2, 3
Progestin-containing intrauterine devices (IUDs) effectively reduce bleeding symptoms and should be considered for long-term management, with a high strength of evidence 2, 3
GnRH agonists and oral GnRH antagonists effectively reduce bleeding symptoms and significantly decrease fibroid volume by 18-30%, with a moderate to high strength of evidence 2, 3
Combination treatment with low doses of estrogen and progestin (add-back therapy) mitigates hypoestrogenic side effects of GnRH modulators and is FDA-approved for fibroid-related heavy menstrual bleeding, with a high strength of evidence 4, 2

Hysterectomy provides definitive resolution of all fibroid-related symptoms and remains the most common treatment for uterine fibroids in the United States, with a high strength of evidence 4, 3
Hysterectomy should be performed via the least invasive route possible to minimize complications, with a moderate to high strength of evidence 4
Important considerations with hysterectomy include potential long-term effects such as increased risk of cardiovascular disease, osteoporosis, and dementia, with a moderate strength of evidence 4

Uterine Artery Embolization (UAE) is effective for patients desiring uterus-preserving therapy, improving symptom scores and quality of life for up to 7 years, with a moderate to high strength of evidence 2, 3
UAE demonstrates greater reduction in fibroid diameter (53%) compared to laparoscopic uterine artery occlusion (39%), with a moderate strength of evidence 2
MR-guided Focused Ultrasound (MRgFUS) is another option but has a higher reintervention rate (30%) compared to UAE (13%), with a moderate strength of evidence 2, 3
For pedunculated submucosal fibroids, MRgFUS can decrease fibroid volume by 66% with significant improvement in symptom scores, with a moderate to high strength of evidence 4

For reproductive age patients with desire for future fertility, start with NSAIDs, tranexamic acid, or hormonal contraceptives for mild symptoms, with a moderate strength of evidence 2
For moderate-severe symptoms, consider short-term GnRH modulators with add-back therapy to reduce fibroid size, with a moderate to high strength of evidence 2
Hysteroscopic myomectomy for submucosal fibroids <5cm; laparoscopic or open myomectomy for other fibroids, with a moderate to high strength of evidence 1, 2
For postmenopausal patients, hysterectomy is usually appropriate for symptomatic fibroids and negative endometrial biopsy, with a high strength of evidence 4, 1

Always rule out malignancy with endometrial biopsy, particularly in postmenopausal patients with fibroid growth or abnormal bleeding, with a high strength of evidence 4
Reintervention rate after UAE is approximately 7% for persistent symptoms, with a moderate strength of evidence 3
Cessation of GnRH modulator therapy leads to rapid recurrence of symptoms, with a moderate to high strength of evidence 4
Hysterectomy should be avoided if a less invasive procedure can provide adequate symptom relief due to higher complication rates, with a moderate to high strength of evidence 4